Back Login for AI Analysis

    TBPH (STOCKS)

    Theravance Biopharma, Inc.

    $16.920000
    +0.000000 (+0.00%)
    Prev close: $16.920000
    Company Information
    Exchange
    XNAS
    Sector
    Health Technology
    Industry
    Pharmaceuticals: Major
    CEO
    Rick E. Winningham
    Asset Type
    stocks
    Website
    Visit
    Fundamentals
    Market Cap
    $881.07M
    Employees
    97
    P/E (TTM)
    16.76
    P/B (TTM)
    3.03
    Dividend Yield
    Technical Indicators
    SMA 10
    SMA 20
    SMA 50
    EMA 9
    EMA 21
    RSI
    MACD State
    Recent News

    No recent news found for this ticker.

    Financial Statements
    TTM (Jun 2026)
    Revenues $104.31M
    Benefits Costs and Expenses $49.69M
    Costs And Expenses $102.02M
    Operating Expenses $108.51M
    Selling, General, and Administrative Expenses $68.75M
    Research and Development $26.01M
    Operating Income/Loss -$4.20M
    Income/Loss From Continuing Operations After Tax $53.81M
    Income/Loss From Continuing Operations Before Tax $31.74M
    Income Tax Expense/Benefit $5.11M
    Net Income/Loss $53.81M
    Net Income/Loss Attributable To Noncontrolling Interest $0.00
    Net Income/Loss Attributable To Parent $53.81M
    Net Income/Loss Available To Common Stockholders, Basic $53.81M
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic $0.00
    Preferred Stock Dividends And Other Adjustments $0.00
    Basic Earnings Per Share $1.06
    Diluted Earnings Per Share $1.01
    Basic Average Shares 102,174,000
    Diluted Average Shares 103,913,000
    Assets $469.77M
    Current Assets $416.66M
    Noncurrent Assets $53.11M
    Fixed Assets $5.17M
    Other Non-current Assets $47.94M
    Liabilities $180.07M
    Current Liabilities $30.77M
    Accounts Payable $652.00K
    Wages $7.83M
    Other Current Liabilities $22.29M
    Noncurrent Liabilities $149.30M
    Equity $289.71M
    Equity Attributable To Noncontrolling Interest $0.00
    Equity Attributable To Parent $289.71M
    Liabilities And Equity $469.77M
    Net Cash Flow From Operating Activities $53.74M
    Net Cash Flow From Operating Activities, Continuing $53.74M
    Net Cash Flow From Investing Activities -$107.47M
    Net Cash Flow From Investing Activities, Continuing -$107.47M
    Net Cash Flow From Financing Activities -$8.44M
    Net Cash Flow From Financing Activities, Continuing -$8.44M
    Net Cash Flow -$62.16M
    Net Cash Flow, Continuing -$62.16M
    Comprehensive Income/Loss $53.67M
    Comprehensive Income/Loss Attributable To Noncontrolling Interest $0.00
    Comprehensive Income/Loss Attributable To Parent $53.71M
    Other Comprehensive Income/Loss -$137.00K